跳至主要内容
临床试验/NL-OMON22976
NL-OMON22976尚未招募不适用

Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations

The Rotterdam Eye Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational non invasive

入排标准

入选标准

  • Be able to cooperate.
  • - Informed consent.
  • - Clinical diagnosis of IRD with confirmed bi-allelic RPE65 mutations.
  • - Clinical evidence of viable retinal tissue (RPE cells, photoreceptors, and downstream ganglion cells) as target. Patients have to have more than one
  • characteristic:
  • 1. total retinal thickness > 100 µm in the posterior pole (OCT).
  • 2. area without atrophy of at least three disc diameters (funduscopy).
  • 3. residual island in the central visual field (within 30º of central fixation; Goldmann).
  • - Recordable FST.
  • - Scheduled to receive treatment with Luxturna®.

排除标准

  • - None specified.

研究者

发起方
The Rotterdam Eye Hospital

相似试验